BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30850577)

  • 1. CBFβ-MYH11 interferes with megakaryocyte differentiation via modulating a gene program that includes GATA2 and KLF1.
    Yi G; Mandoli A; Jussen L; Tijchon E; van Bergen MGJM; Cordonnier G; Hansen M; Kim B; Nguyen LN; Jansen PWTC; Vermeulen M; van der Reijden B; van den Akker E; Bond J; Martens JHA
    Blood Cancer J; 2019 Mar; 9(3):33. PubMed ID: 30850577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia.
    Mandoli A; Singh AA; Jansen PW; Wierenga AT; Riahi H; Franci G; Prange K; Saeed S; Vellenga E; Vermeulen M; Stunnenberg HG; Martens JH
    Leukemia; 2014 Apr; 28(4):770-8. PubMed ID: 24002588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RUNX1 represses the erythroid gene expression program during megakaryocytic differentiation.
    Kuvardina ON; Herglotz J; Kolodziej S; Kohrs N; Herkt S; Wojcik B; Oellerich T; Corso J; Behrens K; Kumar A; Hussong H; Urlaub H; Koch J; Serve H; Bonig H; Stocking C; Rieger MA; Lausen J
    Blood; 2015 Jun; 125(23):3570-9. PubMed ID: 25911237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11.
    Hyde RK; Kamikubo Y; Anderson S; Kirby M; Alemu L; Zhao L; Liu PP
    Blood; 2010 Feb; 115(7):1433-43. PubMed ID: 20007544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice.
    Saida S; Zhen T; Kim E; Yu K; Lopez G; McReynolds LJ; Liu PP
    Leukemia; 2020 Mar; 34(3):759-770. PubMed ID: 31624376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression.
    Xiaosu Z; Leqing C; Yazhen Q; Yu W; Xiaohui Z; Lanping X; Xiaojun H; Yingjun C
    Ann Hematol; 2019 Jan; 98(1):73-81. PubMed ID: 30159599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular analysis of a new variant of the CBF beta-MYH11 gene fusion.
    Stulberg J; Kamel-Reid S; Chun K; Tokunaga J; Wells RA
    Leuk Lymphoma; 2002 Oct; 43(10):2021-6. PubMed ID: 12481902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valproic acid triggers erythro/megakaryocyte lineage decision through induction of GFI1B and MLLT3 expression.
    Zini R; Norfo R; Ferrari F; Bianchi E; Salati S; Pennucci V; Sacchi G; Carboni C; Ceccherelli GB; Tagliafico E; Ferrari S; Manfredini R;
    Exp Hematol; 2012 Dec; 40(12):1043-1054.e6. PubMed ID: 22885124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
    Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
    Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.
    Elmaagacli AH; Beelen DW; Kroll M; Trzensky S; Stein C; Schaefer UW
    Bone Marrow Transplant; 1998 Jan; 21(2):159-66. PubMed ID: 9489633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.
    Richter LE; Wang Y; Becker ME; Coburn RA; Williams JT; Amador C; Hyde RK
    Mol Cancer Res; 2019 Jun; 17(6):1241-1252. PubMed ID: 30814129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare type I CBFβ/MYH11 fusion transcript in primary acute myeloid leukemia with inv(16)(p13.1q22): a case report.
    Zhang W; Wang H; Zhang P; Li H; Ma X; Liu H
    Braz J Med Biol Res; 2021; 54(12):e11605. PubMed ID: 34730684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia.
    Marcucci G; Caligiuri MA; Döhner H; Archer KJ; Schlenk RF; Döhner K; Maghraby EA; Bloomfield CD
    Leukemia; 2001 Jul; 15(7):1072-80. PubMed ID: 11455976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.
    Castilla LH; Bushweller JH
    Adv Exp Med Biol; 2017; 962():229-244. PubMed ID: 28299661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RUNX1 and CBFβ-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.
    Zhen T; Cao Y; Ren G; Zhao L; Hyde RK; Lopez G; Feng D; Alemu L; Zhao K; Liu PP
    Blood; 2020 Nov; 136(21):2373-2385. PubMed ID: 32929473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Divergent functions of hematopoietic transcription factors in lineage priming and differentiation during erythro-megakaryopoiesis.
    Pimkin M; Kossenkov AV; Mishra T; Morrissey CS; Wu W; Keller CA; Blobel GA; Lee D; Beer MA; Hardison RC; Weiss MJ
    Genome Res; 2014 Dec; 24(12):1932-44. PubMed ID: 25319996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Over-expression of CYP2E1 mRNA and protein: implications of xenobiotic induced damage in patients with de novo acute myeloid leukemia with inv(16)(p13.1q22); CBFβ-MYH11.
    Kanagal-Shamanna R; Zhao W; Vadhan-Raj S; Nguyen MH; Fernandez MH; Medeiros LJ; Bueso-Ramos CE
    Int J Environ Res Public Health; 2012 Aug; 9(8):2788-800. PubMed ID: 23066397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia.
    Richter L; Wang Y; Hyde RK
    Oncotarget; 2016 Oct; 7(40):66255-66266. PubMed ID: 27542261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common gene expression signatures in t(8;21)- and inv(16)-acute myeloid leukaemia.
    Ichikawa H; Tanabe K; Mizushima H; Hayashi Y; Mizutani S; Ishii E; Hongo T; Kikuchi A; Satake M
    Br J Haematol; 2006 Nov; 135(3):336-47. PubMed ID: 16989659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct competition between DNA binding factors highlights the role of Krüppel-like Factor 1 in the erythroid/megakaryocyte switch.
    Norton LJ; Hallal S; Stout ES; Funnell APW; Pearson RCM; Crossley M; Quinlan KGR
    Sci Rep; 2017 Jun; 7(1):3137. PubMed ID: 28600522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.